Equities Analysts Issue Forecasts for ORIC Q2 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Analysts at HC Wainwright dropped their Q2 2025 EPS estimates for shares of ORIC Pharmaceuticals in a report released on Monday, January 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.55) for the quarter, down from their prior estimate of ($0.54). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS.

Other equities research analysts also recently issued research reports about the company. Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday. Finally, Wells Fargo & Company began coverage on shares of ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an “overweight” rating and a $20.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $18.29.

ORIC Pharmaceuticals Price Performance

Shares of ORIC stock opened at $10.87 on Thursday. The stock has a 50 day simple moving average of $9.01 and a 200-day simple moving average of $9.46. ORIC Pharmaceuticals has a 12-month low of $6.33 and a 12-month high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.01).

Insider Buying and Selling at ORIC Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 8,851 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the transaction, the chief financial officer now directly owns 106,764 shares of the company’s stock, valued at $884,005.92. The trade was a 7.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jacob Chacko sold 24,660 shares of ORIC Pharmaceuticals stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the sale, the chief executive officer now owns 778,648 shares of the company’s stock, valued at approximately $6,447,205.44. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,361 shares of company stock valued at $350,749 over the last quarter. Corporate insiders own 5.55% of the company’s stock.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ORIC. Charles Schwab Investment Management Inc. grew its stake in ORIC Pharmaceuticals by 152.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock worth $4,205,000 after acquiring an additional 247,863 shares during the period. Franklin Resources Inc. boosted its holdings in shares of ORIC Pharmaceuticals by 26.1% during the third quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after purchasing an additional 196,804 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of ORIC Pharmaceuticals by 62.0% in the second quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company’s stock valued at $1,318,000 after purchasing an additional 71,394 shares during the period. Creative Planning acquired a new position in ORIC Pharmaceuticals in the third quarter valued at $116,000. Finally, Barclays PLC increased its stake in ORIC Pharmaceuticals by 111.2% in the third quarter. Barclays PLC now owns 107,261 shares of the company’s stock valued at $1,100,000 after purchasing an additional 56,474 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.